Alon Lazarus
Directeur/Bestuurslid bij WEREWOLF THERAPEUTICS, INC.
Vermogen: - $ op 30-04-2024
Profiel
Alon Lazarus is currently serving as a Director at Locki Therapeutics Ltd., Bluejay Therapeutics, Inc., Lutris Pharma Ltd., Paros Bio, Inc., Werewolf Therapeutics, Inc., Entact Bio, Inc., Photys Therapeutics, Inc., Auron Therapeutics, Inc., and Arkin Bio Ventures.
He started his role as a Biotech Investment Manager at Arkin Bio Ventures in 2013.
Previously, he held positions as a Director at Pantheon Biosciences Ltd., Oncorus, Inc., Keros Therapeutics, Inc., Quiet Therapeutics Ltd., and Manager-Biotech Investment at Arkin Holdings.
He also worked as an Analyst at Integra Holdings Ltd.
and as the Head of Business Development at Yissum Holdings Ltd.
Dr. Lazarus holds a doctorate degree from The Hebrew University Hadassah Medical School and undergraduate and MBA degrees from The Hebrew University of Jerusalem.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
21-06-2023 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Alon Lazarus
Bedrijven | Functie | Begin |
---|---|---|
WEREWOLF THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-08-2019 |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | Directeur/Bestuurslid | - |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | Directeur/Bestuurslid | - |
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Directeur/Bestuurslid | 08-11-2019 |
Photys Therapeutics, Inc.
Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Directeur/Bestuurslid | - |
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Directeur/Bestuurslid | - |
Arkin Bio Ventures
Arkin Bio Ventures Investment ManagersFinance Arkin Bio Ventures (Arkin Bio) is a venture capital arm of Arkin Holdings founded in 2016. The firm is headquartered in Tel Aviv, Israel. | Private Equity Investor | 01-08-2013 |
Lutris Pharma Ltd.
Lutris Pharma Ltd. Pharmaceuticals: MajorHealth Technology Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel. | Directeur/Bestuurslid | - |
Entact Bio, Inc.
Entact Bio, Inc. BiotechnologyHealth Technology Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Alon Lazarus
Bedrijven | Functie | Einde |
---|---|---|
░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Opleiding van Alon Lazarus
The Hebrew University of Jerusalem | Masters Business Admin |
The Hebrew University Hadassah Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
ONCORUS, INC. | Health Technology |
KEROS THERAPEUTICS, INC. | Health Technology |
WEREWOLF THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 13 |
---|---|
Yissum Holdings Ltd. | |
Quiet Therapeutics Ltd.
Quiet Therapeutics Ltd. Medical SpecialtiesHealth Technology Quiet Therapeutics Ltd. develops a proprietary nanoparticle-based delivery system for the targeted delivery of chemotherapy and anti-inflammatory drugs. It developed a class of cancer therapeutics called GAGomers, enables the flexibility of delivering a medicine that can kill the cancer cells and block the production of proteins that promote the cancer. The company was founded by Dan Peer and Rimona Margalit in 2009 and is headquartered in Ness Ziona, Israel. | Health Technology |
Integra Holdings Ltd.
Integra Holdings Ltd. MiscellaneousMiscellaneous Integra Holdings Ltd. operates as a holding company. It invests in the pharmaceutical industry. The company was founded in 2012 and is headquartered in Jerusalem, Israel. | Miscellaneous |
Arkin Bio Ventures
Arkin Bio Ventures Investment ManagersFinance Arkin Bio Ventures (Arkin Bio) is a venture capital arm of Arkin Holdings founded in 2016. The firm is headquartered in Tel Aviv, Israel. | Finance |
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Commercial Services |
Lutris Pharma Ltd.
Lutris Pharma Ltd. Pharmaceuticals: MajorHealth Technology Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel. | Health Technology |
Arkin Holdings
Arkin Holdings Real Estate Investment TrustsFinance Arkin Holdings engages in the provision of healthcare investment services which specializes in pharmaceutical and biotechnology, medical devices, dermatology, and hedge fund. The company was founded by Mori Arkin in 2009 and is headquartered in Herzliya, Israel. | Finance |
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Health Technology |
Pantheon Biosciences Ltd.
Pantheon Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Pantheon Biosciences Ltd. is an Israeli company that develops molecular therapies and tools. The company is based in Yavne, Israel and was founded in 2017. | Commercial Services |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | Commercial Services |
Photys Therapeutics, Inc.
Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Health Technology |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | Health Technology |
Entact Bio, Inc.
Entact Bio, Inc. BiotechnologyHealth Technology Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions. | Health Technology |